Heramed Limited Stock: price and insider trades · Australia

Heramed Limited belongs to the Health Care sector. Filings by its managers are published through ASX. Over the twelve months to 18 October 2026, 3 filings were filed, from 2 insiders.

Open-market activity splits into 1 purchase and 2 sales; 1 insider sit on the buying side and 2 insiders on the selling side. The amount is not disclosed for 3 filings. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The buyers include 1 senior executive.

The latest purchase dates back some time: it was published 174 days ago, on 27 April 2026. Typically, a trade is published a median of 4 days after it takes place. That lag is the time during which only the insider knows about the trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.

Across the 2,530 companies tracked on its exchange, the median is 3 filings; at 3 filings, this issuer sits right on that mark. Over the whole record (from 2026), the tally stands at 1 purchase and 2 sales.

Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by ASX. They describe what insiders did and are not a recommendation.